Guest Columns
-
Liquid Biopsy Early Cancer Detection Diagnostics: The Current Landscape
12/7/2022
The most impactful driver of cancer survival in the future may not come from therapies, but rather from the diagnostic tools, especially liquid biopsies, that inform which, when, and how patients should be treated. This article provides an in-depth landscape assessment of liquid biopsies for diagnostics developers.
-
Rising Interest Rates Skew Risk-Return Paradigm For Life Sciences
12/6/2022
Rising interest rates, imploding cryptocurrencies, and erratic equities markets have upended assumptions about risk and returns during 2022. The “risk-free” rate has surged to more than 4% as of late November. Your pharma, biotech, or medical device company looking to raise cash needs to take the key considerations shared in this article into account.
-
The Global Cardiac Rhythm Management Market Through 2028
12/5/2022
This article provides a market research overview on the cardiac rhythm management market (both diagnostics and medical devices) as well as the main drivers for growth.
-
5 Steps To Eliminate Weak Links In Your Data Governance
12/2/2022
Major regulators including the FDA and EMA have established frameworks through which data must be captured and exchanged with them. But your pharma, biotech, or medical device company needs a solid plan for how that data will be governed.
-
How Can AI-Powered Advanced Imaging Battle Long COVID?
11/30/2022
Long COVID is not a rare disease — over 100 million worldwide likely have it — so why do we still lack the proper infrastructure to tackle and understand it? There are two key areas that delay progress: data collection and symptom interpretation. Both can be assisted by AI-enhanced technologies.
-
The Lasting Impact Of Telehealth On Dermatology May Only Be Skin Deep
11/28/2022
Immunological diseases received particular focus during the pandemic’s telehealth boom due to COVID-19’s disproportional effect on immunocompromised patients. Teledermatology apps saw a sharp increase in use. But is telehealth truly meeting the needs for dermatology?
-
What’s Wrong With The Medtech R&D Department?
11/22/2022
Executives, staff members, and investors of medical device companies commonly ask, “What’s wrong with the R&D department? What’s taking so long?" This article discusses five common culprits and the common thread solution that could solve all of them.
-
FDA Vs. Congress: The Software Showdown
11/14/2022
September 2022 will be remembered as a seminal turning point in digital health in the U.S. With the FDA’s final guidance on Clinical Decision Support (CDS) software, the FDA disregards a Congressional directive when it enacted the 21st Century Cures Act in 2016.
-
LATAM’s Regulatory Framework For Medtech Early Feasibility Studies
11/11/2022
Latin America is a compelling region to conduct medtech early feasibility studies due to its ethnically diverse population, its high rate of urbanization, and more. Here, the author spotlights Colombia, Brazil, and Mexico as the hotspots for medtech feasibility studies in Latin America.
-
The Upper Nasal Space: Drug Delivery’s Next Frontier
11/9/2022
Oral formulations of drugs account for up to 75% of prescriptions. However, many diseases require therapies to provide a maximal benefit as quickly as possible, and oral delivery may result in slow absorption. Enter drug delivery via the upper nasal space, which has the potential to provide a more rapid onset of activity, avoid degradation in the GI tract, and more benefits.